Circulation

NOVEMBER 11, 2024

3.04, p<0.001), and stroke (HR: 1.70, 95%CI: 1.45 – 2.00, p<0.001) were all higher in MAC patients than non-MAC patients (table 1).Conclusion:Among Circulation, Volume 150, Issue Suppl_1 , Page A4140591-A4140591, November 12, 2024.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Bicuspid/Mitral Outcomes 40

DAIC

FEBRUARY 29, 2024

24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

DAIC

MARCH 26, 2025

live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. 4 Approximately 6.7 million adults in the U.S. Bozkurt A, et al.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

Circulation

OCTOBER 13, 2023

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population. per 100 patient-years).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction 40

European Journal of Heart Failure

NOVEMBER 3, 2024

The role of ablation-based rhythm control in patients with AF and HF with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) is not known. Methods CABA-HFPEF-DZHK27 (NCT05508256) is an investigator-initiated, prospective, randomized, open, interventional multicentre strategy trial with blinded outcome assessment.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

European Journal of Heart Failure

OCTOBER 5, 2023

Abstract Aims Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) are often treated with calcium channel blockers (CCBs), although the safety of CCBs in these patients is uncertain. 0.96), while the risk of stroke was higher (HR 1.26, 95% CI 1.06–1.50)

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outcomes Hospital 40

Open Heart

JANUARY 8, 2024

The secondary outcomes were composite major adverse cardiac events (MACE) (study defined), myocardial infarction (MI), stroke, cardiac death, sudden death, the development of symptoms, heart failure hospitalisations and major bleeding. We noticed no difference in MI, stroke and major bleeding. to 1.1), I 2 =31%, p=0.09).

Aortic valve 98

Aortic valve Aortic Preserved Ejection Fraction Stenosis 98

DAIC

APRIL 2, 2024

Breaking the data down by type of heart failure, the increased risk associated with e-cigarette use was statistically significant for heart failure with preserved ejection fraction (HFpEF)—in which the heart muscle becomes stiff and does not properly fill with blood between contractions.

Heart Failure 105

Heart Failure Preserved Ejection Fraction Research Risk Factors 105

Open Heart

JANUARY 18, 2024

Background The Heart Failure Association Pretest assessment, echocardiography and natriuretic peptide, functional testing and final aetiology (HFA-PEFF) score has been developed for diagnosing heart failure with preserved ejection fraction (HFpEF), which is frequently associated with atrial fibrillation (AF).

Atrial Fibrillation 52

Atrial Fibrillation Preserved Ejection Fraction Ablation Outcomes 52

Frontiers in Cardiovascular Medicine

AUGUST 6, 2024

In the long term, a history of gestational hypertension and pre-eclampsia significantly increases the risk of future cardiovascular disease including chronic hypertension, coronary artery disease, heart failure and stroke.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Coronary Artery Disease Hypertension 40

Dr. Smith's ECG Blog

OCTOBER 28, 2023

LVH is a common etiology of heart failure with preserved ejection fraction, as it may results in a stiff ventricle with poor diastolic relaxation. There is very little filling, and thus very poor stroke volume. LVH can have very thick-walled ventricles and a correspondingly small LV cavity. It is only a slit.

Preserved Ejection Fraction 56

Preserved Ejection Fraction Sudden Cardiac Death Chest Pain Heart Failure 56

Heart BMJ

NOVEMBER 27, 2023

They included 9 patients with rEF (EF <50%) and 12 with preserved ejection fraction (pEF) (EF >50%). Load-independent contractile function was similar between the rEF and pEF groups: preload recruitable stroke work slope (101 vs 112 mm Hg; p=0.65), end-systolic pressure-volume relationship slope (1.91

Stenosis 40

Stenosis Aortic Preserved Ejection Fraction Aortic valve 40

Cardiometabolic Health Congress

JULY 25, 2023

4] More recently, at least at the epidemiologic level, the obesity paradox has been confirmed in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), but also in those with coronary heart disease. [5, Carbone, Salvatore, et al. Future Cardiology 13.5

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiology Update

APRIL 9, 2024

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. The primary endpoint consisted of a composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF).

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59